Latest news with #Agilent
Yahoo
5 days ago
- Business
- Yahoo
Lightcast Appoints Industry Veteran Philip Binns as Chairman of the Board
Former Agilent executive to help guide commercial growth strategies for groundbreaking benchtop single-cell functional analysis platform CAMBRIDGE, England & CAMBRIDGE, Mass., June 02, 2025--(BUSINESS WIRE)--Lightcast, a pioneering life science tools company, today announced the appointment of Philip Binns as chairman of its board of directors, effective May 1, 2025. With this appointment, the Lightcast board includes one investor director each from Arch Ventures, Illumina Ventures, M-Ventures, and Longwall Ventures; two independent directors, Kevin Knopp, CEO of 908 Devices, and Kevin Hrusovsky, chairman and former CEO of Quanterix; and observers from OMX Ventures, +ND Capital, and Terra Magnum. "We are thrilled to add Phil to our highly experienced board," said Paul Loeffen, PhD, CEO of Lightcast. "His extensive industry expertise and proven leadership will be invaluable as we evolve from a product development-focused company into a fully commercial organization, expanding our global reach and maximizing our impact in the life sciences market." Mr. Binns brings decades of experience in scientific instrumentation and leadership, recently serving as president of the life sciences and applied markets group at Agilent Technologies. He joined Agilent in 2010 through its acquisition of Varian, Inc., where he played a pivotal role in expanding the company's atomic and molecular spectroscopy portfolio into a market-leading business. In addition to his new role at Lightcast, Mr. Binns serves as chair and non-executive director of Epiminder, a company developing implantable brain-monitoring devices; as a director of the Bionics Institute, a globally recognized medical device research organization; and as a National Council Advisor to the Australian Industry AI Group. He holds a degree in business management from the University of Melbourne and an MBA from Melbourne Business School. "The Lightcast Envisia™ platform has the potential to transform single-cell analysis by unlocking functional insights that were previously out of reach," said Binns. "The company is at an exciting inflection point, and I'm eager to collaborate with this talented team to support the platform's global adoption and help drive the next generation of biologics and therapies." While traditional single-cell analysis techniques often rely on genomic data to infer function, the benchtop Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology. Lightcast recently announced the limited commercial release of its Envisia benchtop platform. The company is actively collaborating with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas. These efforts will support the full commercial launch of a comprehensive suite of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized for a broad range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit About Lightcast Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd. View source version on Contacts For further information Andrew Noble for Lightcastandrew@ +1 (415) 722-2129 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
A Q2 Earnings Call: Mixed Revenue Performance, Margin Pressure, and Strategic Updates
Life sciences tools company Agilent Technologies (NYSE:A) fell short of the market's revenue expectations in Q1 CY2025, but sales rose 6% year on year to $1.67 billion. Its non-GAAP EPS of $1.31 per share was 3.6% above analysts' consensus estimates. Is now the time to buy A? Find out in our full research report (it's free). Revenue: $1.67 billion (6% year-on-year growth) Adjusted EPS: $1.31 vs analyst estimates of $1.26 (3.6% beat) Adjusted Operating Income: $419 million vs analyst estimates of $409.9 million (25.1% margin, 2.2% beat) Revenue Guidance for Q2 CY2025 is $1.66 billion at the midpoint, above analyst estimates of $1.65 billion Management reiterated its full-year Adjusted EPS guidance of $5.58 at the midpoint Operating Margin: 18%, down from 23.1% in the same quarter last year Organic Revenue rose 5.1% year on year (-7.4% in the same quarter last year) Market Capitalization: $31.61 billion Agilent's second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase in digital orders, and pointed to operational changes—including the Ignite transformation initiative—that drove early wins in pricing and procurement. While most end markets performed as expected, academia and government remained soft, and management described the macroeconomic and geopolitical environment as 'highly dynamic,' underscoring ongoing uncertainty. Looking forward, Agilent's guidance is shaped by ongoing tariff risks, a cautious approach to macroeconomic uncertainty, and confidence in its operational initiatives. Management maintained its full-year core growth and adjusted EPS outlook, citing the ability to offset incremental tariff costs through supply chain adjustments, pricing, and Ignite-driven efficiencies. CFO Bob McMahon noted, 'A combination of supply chain moves, surcharges, and savings will allow us to fully mitigate tariff costs by next year.' The company expects continued momentum in PFAS testing, accelerating growth in its CDMO (contract development and manufacturing organization) segment, and further gains from newly launched products such as the Infinity III LC system and Seahorse XF Flex analyzer. However, management cautioned that near-term growth may be uneven given the dynamic external environment and timing of customer orders. Management pointed to diverse geographic and product performance, with China and environmental testing outpacing expectations, while transformative operational initiatives helped offset mounting tariff pressures. China and India outperformance: China delivered 10% growth, benefiting from stable demand and a favorable Lunar New Year comparison, while India posted high-teens growth. Management opened its first India solution center to support local demand for advanced testing and regulatory compliance. PFAS testing momentum: Agilent saw more than 70% year-over-year growth in PFAS testing, driven by global regulatory expansion and product innovation. The company cited its Infinity III and 6495D systems as increasingly critical for customers seeking sensitive, robust PFAS detection in water, food, and industrial materials. Biopharma and CDMO progress: The NASD (Nucleic Acid Solutions Division) and BIOVECTRA businesses reported high single-digit and high teens growth, respectively. Management highlighted improved visibility on future orders, with the BIOVECTRA acquisition expanding Agilent's presence in GLP-1 and complex chemistries manufacturing. Operational transformation via Ignite: The Ignite initiative enabled enterprise-wide pricing, organizational streamlining, and procurement centralization, leading to over $130 million in expected profit contribution for the year. The company achieved full-year pricing realization targets within six months and projects $80 million in annualized savings from organizational changes. Tariff mitigation and supply chain agility: Agilent's tariff task force responded quickly to shifts in US, China, and EU tariffs by moving production, centralizing procurement, and implementing targeted price surcharges. Management expects to fully offset tariff impacts in 2026, with minimal net impact for this year despite potential new EU tariff increases. Agilent's outlook for the coming quarters hinges on successful tariff mitigation, continued product innovation, and steady demand in core end markets, balanced against macroeconomic uncertainty. Tariff mitigation and pricing actions: Management anticipates covering all incremental tariff costs in 2025 through a blend of supply chain adjustments, strategic pricing surcharges, and Ignite-driven procurement savings. The company expects these actions to fully neutralize tariff impacts by next year, though the evolving trade landscape remains a risk. Momentum in PFAS and CDMO segments: Agilent projects ongoing strength in PFAS testing, driven by expanding global regulations and the company's technology leadership. The CDMO segment (NASD and BIOVECTRA) is expected to deliver double-digit growth in the second half, supported by a healthy order backlog and accelerating commercialization of new manufacturing programs. Replacement cycles and product launches: The adoption of new instruments, notably the Infinity III LC system, is fueling replacement cycles across pharma, environmental, and food testing labs. Management highlighted higher attach rates for services and consumables, and expects sales momentum to build as customers upgrade aging systems over the next several quarters. In the coming quarters, the StockStory team will watch for (1) sustained momentum in PFAS testing and CDMO segment order growth, (2) evidence that Ignite-driven cost savings and pricing actions are offsetting tariff impacts and supporting margin stability, and (3) the pace of customer adoption for new instruments like the Infinity III LC system. Progress in these areas will be key to tracking Agilent's ability to navigate external headwinds and deliver on its operational commitments. Agilent currently trades at a forward P/E ratio of 19.1×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook
Agilent Technologies Inc. (NYSE:A) reported second-quarter 2025 sales of $1.67 billion on Wednesday, almost in line with the consensus of $1.63 billion, representing growth of 6% reported and up 5.3% core year-over-year. The Life Sciences and Diagnostics Markets Group (LDG) reported second-quarter revenue of $654 million, an increase of 8% reported and 3% core year-over-year. LDG's operating margin for the quarter was 19.7%. The Agilent CrossLab Group (ACG) reported second-quarter revenue of $713 million, an increase of 7% reported and 9% core year-over-year. ACG's operating margin for the quarter was 32.4%. The Applied Markets Group (AMG) reported second-quarter revenue of $301 million, a decrease of 1% reported and flat core year-over-year. AMG's operating margin for the quarter was 19.5%.The analytical and clinical laboratory technologies provider reported adjusted earnings of $1.31 per share, up from $1.22 a year ago, beating the consensus of $1.26. 'The Agilent team delivered strong second-quarter results in a highly dynamic market environment,' said Agilent President and CEO Padraig McDonnell. 'That is in large part due to our Ignite Transformation, which is driving our financial success as it's become our core enterprise delivery engine and operating model. Ignite represents a decisive shift to fuel accelerated profitable growth and operational excellence at Agilent.' The company's operating margin was 25.1% as it absorbed some incremental tariff costs. In the earnings conference call, McDonnell said, 'Through our tariff task force enabled by our Ignite operating model, we feel that we are able to mitigate most of the impact in 2025 and fully mitigate in 2026 even when considering recent developments on the U.S.-EU tariffs.' Agilent reaffirmed fiscal 2025 adjusted earnings of $5.54-$5.61 per share compared to the consensus of $5.55. The company raised sales guidance from $6.68 billion-$6.76 billion to $6.73 billion-$6.81 billion compared to the consensus of $6.73 billion. The full-year revenue outlook represents growth of 3.4%-4.6% reported while maintaining core growth of 2.5%-3.5% Based on the current tariff rates, Agilent estimates that the gross incremental tariff exposure in the second half will be $50 million. This is on top of the roughly $10 million already absorbed in the first half. The company anticipates potential additional tariff impacts if U.S.-EU tariffs increase, which could add $40 million in gross exposure in the second half of 2025. The outlook for third-quarter revenue is expected to be $1.65 billion-$1.68 billion versus a consensus of $1.65 billion, representing a growth of 4.2% to 6.1% reported and up 1.7% to 3.6% core. Agilent sees Q3 adjusted earnings of $1.35-$1.37 versus a consensus of $1.39. Price Action: A stock is trading higher by 5.52% to $117 premarket at last check Thursday. Read Next:Image via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? AGILENT TECHNOLOGIES (A): Free Stock Analysis Report This article Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Agilent Technologies (A) Q2 Earnings and Revenues Top Estimates
Agilent Technologies (A) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.97%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.27 per share when it actually produced earnings of $1.31, delivering a surprise of 3.15%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Agilent , which belongs to the Zacks Medical - Products industry, posted revenues of $1.67 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.64%. This compares to year-ago revenues of $1.57 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Agilent shares have lost about 17.2% since the beginning of the year versus the S&P 500's gain of 0.7%. While Agilent has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Agilent: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.40 on $1.65 billion in revenues for the coming quarter and $5.54 on $6.73 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, Aurora Cannabis Inc. (ACB), is yet to report results for the quarter ended March 2025. This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Aurora Cannabis Inc.'s revenues are expected to be $62.4 million, up 24.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Here's What Key Metrics Tell Us About Agilent (A) Q2 Earnings
For the quarter ended April 2025, Agilent Technologies (A) reported revenue of $1.67 billion, up 6% over the same period last year. EPS came in at $1.31, compared to $1.22 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.63 billion, representing a surprise of +2.64%. The company delivered an EPS surprise of +3.97%, with the consensus EPS estimate being $1.26. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Agilent performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue by End Markets- Pharmaceutical: $603 million versus the two-analyst average estimate of $572.63 million. The reported number represents a year-over-year change of +11.3%. Revenue by End Markets- Academia and Government: $135 million compared to the $145.13 million average estimate based on two analysts. The reported number represents a change of -2.9% year over year. Revenue by End Markets- Diagnostics and Clinical: $255 million versus the two-analyst average estimate of $247.93 million. The reported number represents a year-over-year change of +6.7%. Net Revenue- Agilent Crosslab Group: $713 million versus $697.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +77.4% change. Revenue by End Markets- Food: $147 million versus $146.05 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.8% change. Revenue by End Markets- Environmental and Forensics: $159 million compared to the $159.54 million average estimate based on two analysts. The reported number represents a change of +4.6% year over year. Revenue by End Markets- Chemical and advanced materials: $369 million compared to the $370.20 million average estimate based on two analysts. The reported number represents a change of +1.9% year over year. View all Key Company Metrics for Agilent here>>>Shares of Agilent have returned +3.5% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
